A Hierarchy of Harm: A Meta-analysis of Infection, Thrombosis, and Mortality Risks Across Central Catheters, Arteriovenous Grafts, and Fistulas
DOI:
https://doi.org/10.37275/bsm.v9i12.1462Keywords:
Arteriovenous fistula, Arteriovenous graf, Central venous catheter, Hemodialysis, Vascular accessAbstract
Background: Vascular access is a critical lifeline for patients with end-stage kidney disease requiring hemodialysis. The optimal choice among central venous catheters (CVCs), arteriovenous grafts (AVGs), and arteriovenous fistulas (AVFs) is a subject of intense debate, as each modality carries a distinct profile of risks. This meta-analysis was performed to establish a definitive, quantitative hierarchy of these risks to better inform clinical and policy decisions.
Methods: A systematic search of PubMed, Scopus, and the Cochrane Library was conducted for studies published between January 2015 and September 2025 that compared complication rates among CVCs, AVGs, and AVFs in adult hemodialysis patients. Seven high-quality cohort studies met the inclusion criteria, encompassing 18,542 patients. Data on access-related bloodstream infections (ARBSI), access circuit thrombosis/dysfunction, and all-cause mortality were extracted. Pairwise meta-analyses using a random-effects model calculated pooled risk ratios (RR) and 95% confidence intervals (CI).
Results: Central venous catheters were associated with a profoundly higher risk of ARBSI compared to both AVFs (RR 8.12, 95% CI 6.98–9.45, p < 0.001) and AVGs (RR 4.55, 95% CI 3.89–5.33, p < 0.001). Arteriovenous grafts demonstrated a markedly higher risk of access circuit thrombosis compared to AVFs (RR 2.78, 95% CI 2.41–3.21, p < 0.001). All-cause mortality was highest in patients with CVCs, showing a significantly increased risk compared to AVF users (RR 1.92, 95% CI 1.68–2.19, p < 0.001).
Conclusion: This meta-analysis provides robust, contemporary quantitative evidence for a clear hierarchy of harm in hemodialysis access. CVCs pose the greatest risk for infection and mortality, AVGs present the highest risk for thrombosis, and AVFs represent the safest option. These data provide a powerful rationale for reinforcing systemic healthcare initiatives aimed at minimizing CVC exposure and promoting timely AVF placement.
Authors
- Anak Agung Ngurah Gede Anggra Pramana1*
- Anthony Wijaya2
- Putu Chandra Wibawa3
- I Gusti Agung Bagus Krisna Wibawa4
- 1General Practitioner, Bangli Medika Canti Hospital, Bangli, Indonesia
- 2Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia
- 3Staff Vascular & Endovascular Surgery Division, Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Indonesia
- 4Endovascular Division of Department Surgery, Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia
Corresponding author Anak Agung Ngurah Gede Anggra Pramana — anggrapramana02@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
